Literature DB >> 29371406

A Prospective Study of Quantitative SPECT/CT for Evaluation of Lung Shunt Fraction Before SIRT of Liver Tumors.

Helmut Dittmann1, Daniel Kopp2, Juergen Kupferschlaeger2, Diana Feil2, Gerd Groezinger3, Roland Syha3, Matthias Weissinger2, Christian la Fougère2.   

Abstract

The lung shunt fraction (LSF) is estimated using 99mTc-macroaggregated albumin (99mTc-MAA) imaging before selective internal radiotherapy (SIRT) of the liver to reduce the risk of pulmonary irradiation. Generally, planar scans are acquired after injection of 99mTc-MAA into the hepatic artery. However, the validity of this approach is limited by differences in attenuation between liver and lung tissue as well as inaccurate segmentation of the organs. The aim of this study was to evaluate quantitative SPECT/CT for LSF assessment in a prospective clinical cohort.
Methods: Fifty consecutive patients intended to undergo SIRT were imaged within 1 h after injection of 99mTc-MAA using a SPECT/CT γ-camera. Planar scans of the lung and liver region were acquired in anterior and posterior views, followed by SPECT/CT scans of the thorax and abdomen. Emission data were corrected for scatter, attenuation, and resolution recovery using dedicated software. To quantify the radioactivity concentration in the lung, liver, urinary bladder and remainder of the thoracoabdominal body, volumes of interest were defined on the SPECT/CT images. 99mTc-MAA concentrations were calculated as percentage injected dose (%ID).
Results: Mean 99mTc-MAA uptake in liver and lung accounted for only 79 %ID, whereas 13.1 %ID was present in the remainder of the body. In all patients, LSF as calculated from planar scans accounted for a median of 6.8% (range, 3.4%-32.3%), whereas the SPECT/CT quantitation revealed significantly lower LSF estimates, at a median of 1.9% (range, 0.8%-15.7%) (P < 0.0001, Wilcoxon test). On the basis of planar imaging, dose reduction or even contraindications to SIRT had to be considered in 10 of 50 patients, as their LSF was calculated at 10% or more. In contrast, SPECT/CT quantitation showed substantial shunting in only 2 of the 50 patients.
Conclusion: Quantitative SPECT/CT reveals that the LSF is considerably lower than shown on planar imaging. Thus, the resulting dose to the lung parenchyma may be less than conventionally assumed. However, the safety of the SPECT/CT-derived dose range will have to be evaluated.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  SIRT; SPECT/CT; Tc-MAA; lung shunt; radioembolization

Mesh:

Year:  2018        PMID: 29371406     DOI: 10.2967/jnumed.117.205203

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

Review 1.  Clinical Applications of Technetium-99m Quantitative Single-Photon Emission Computed Tomography/Computed Tomography.

Authors:  Won Woo Lee
Journal:  Nucl Med Mol Imaging       Date:  2019-03-15

2.  Using an Assumed Lung Mass Inaccurately Estimates the Lung Absorbed Dose in Patients Undergoing Hepatic 90Yttrium Radioembolization Therapy.

Authors:  Cassidy R Dodson; Colin Marshall; Jared C Durieux; Patrick F Wojtylak; Jon C Davidson; Raymond F Muzic; Arash Kardan
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-04       Impact factor: 2.797

3.  Reduction of Hepatopulmonary and Intrahepatic Shunts after Treatment with Sorafenib in Hepatocellular Carcinoma Patients.

Authors:  Huseyin Tugsan Balli; Kairgeldy Aikimbaev; Isa Guney Burak; Umur Anil Pehlivan; Ferhat Can Piskin; Sinan Sozutok
Journal:  Cardiovasc Intervent Radiol       Date:  2022-09-29       Impact factor: 2.797

4.  Lung Dose Measured on Postradioembolization 90Y PET/CT and Incidence of Radiation Pneumonitis.

Authors:  Martina Stella; Rob van Rooij; Marnix G E H Lam; Hugo W A M de Jong; Arthur J A T Braat
Journal:  J Nucl Med       Date:  2021-11-12       Impact factor: 11.082

5.  International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres.

Authors:  Hugo Levillain; Oreste Bagni; Christophe M Deroose; Arnaud Dieudonné; Silvano Gnesin; Oliver S Grosser; S Cheenu Kappadath; Andrew Kennedy; Nima Kokabi; David M Liu; David C Madoff; Armeen Mahvash; Antonio Martinez de la Cuesta; David C E Ng; Philipp M Paprottka; Cinzia Pettinato; Macarena Rodríguez-Fraile; Riad Salem; Bruno Sangro; Lidia Strigari; Daniel Y Sze; Berlinda J de Wit van der Veen; Patrick Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-12       Impact factor: 9.236

6.  Lung Metastasis Postradioembolization of Hepatocellular Carcinoma With Tumor in Vein.

Authors:  Harit Kapoor; Sreeja Sanampudi; Joseph Owen; Driss Raissi
Journal:  ACG Case Rep J       Date:  2020-03-02

7.  Towards standardization of absolute SPECT/CT quantification: a multi-center and multi-vendor phantom study.

Authors:  Steffie M B Peters; Niels R van der Werf; Marcel Segbers; Floris H P van Velden; Roel Wierts; Koos J A K Blokland; Mark W Konijnenberg; Sergiy V Lazarenko; Eric P Visser; Martin Gotthardt
Journal:  EJNMMI Phys       Date:  2019-12-26

8.  Influence of 99m-Tc-Nanocolloid Activity Concentration on Sentinel Lymph Node Detection in Endometrial Cancer: A Quantitative SPECT/CT Study.

Authors:  Samine Sahbai; Francesco Fiz; Florin Taran; Sara Brucker; Diethelm Wallwiener; Juergen Kupferschlaeger; Christian La Fougère; Helmut Dittmann
Journal:  Diagnostics (Basel)       Date:  2020-09-16

9.  The value of 99mTc-MAA SPECT/CT for lung shunt estimation in 90Y radioembolization: a phantom and patient study.

Authors:  Jonathan D Allred; Jeremy Niedbala; Justin K Mikell; Dawn Owen; Kirk A Frey; Yuni K Dewaraja
Journal:  EJNMMI Res       Date:  2018-06-15       Impact factor: 3.138

10.  Reassessment of the lung dose limits for radioembolization.

Authors:  S Cheenu Kappadath; Benjamin P Lopez; Riad Salem; Marnix G E H Lam
Journal:  Nucl Med Commun       Date:  2021-10-01       Impact factor: 1.690

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.